Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Blepharitis Clear all
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

NCT02218489
View directory record Official record
Conditions
Blepharitis
Interventions
KPI-121, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Patients With Blepharitis and Facial Rosacea

NCT00560703
View directory record Official record
Conditions
Blepharitis, Meibomianitis, Dry Eye
Interventions
COL-101 (doxycycline, USP) capsules, placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Naples, Florida • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Not applicable Interventional

Corneal Epithelial Stem Cells and Dry Eye Disease

NCT03302273
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye, Ocular Inflammation, Ocular Surface Disease, Ocular Discomfort, Blepharitis
Interventions
Corneal Epithelial Stem Cell Transplant
Other
Lead sponsor
Sloan W. Rush, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 21, 2026, 2:11 AM EDT
Not listed Not applicable Interventional

Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora

NCT02455895
View directory record Official record
Conditions
Sebaceous Gland Diseases, Blepharitis
Interventions
iLid Cleanser
Device
Lead sponsor
NovaBay Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Phoenix, Arizona • San Leandro, California • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

NCT04784091
View directory record Official record
Conditions
Blepharitis
Interventions
TP-03, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Northridge, California • San Ramon, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 21, 2026, 2:11 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of SUMMIT BRUSH in Treatment of Blepharitis

NCT04603222
View directory record Official record
Conditions
Blepharitis
Interventions
SUMMIT BRUSH, Ocusoft Lid Scrub Original Foaming Eyelid Cleanser
Device · Other
Lead sponsor
University of Notre Dame
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Boulder, Colorado • Mishawaka, Indiana • Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy Pilot Study of AzaSite® (Azithromycin) in Subjects With Blepharitis

NCT00629980
View directory record Official record
Conditions
Blepharitis
Interventions
AzaSite®
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
9
States / cities
Artesia, California • Mission Hills, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Phase 4 Interventional Results available

Efficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis

NCT01456780
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Posterior Blepharitis
Interventions
Loteprednol/tobramycin, Loteprednol, B+L Advanced Eye Relief Lubricant Drop
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

NCT04475432
View directory record Official record
Conditions
Blepharitis
Interventions
TP-03, 0.25%, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Phoenix, Arizona • Newport Beach, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 21, 2026, 2:11 AM EDT
Terminated Not applicable Interventional

Ocular Comfort and Inflammation in Lid Hygiene Therapy

NCT02938078
View directory record Official record
Conditions
Blepharitis
Interventions
Avenova Lid Cleanser
Device
Lead sponsor
Minnesota Eye Consultants, P.A.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bloomington, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Phase 2 Interventional

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

NCT00892970
View directory record Official record
Conditions
Blepharitis
Interventions
Azithromycin ophthalmic solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
33
States / cities
Little Rock, Arkansas • Artesia, California • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 21, 2026, 2:11 AM EDT
Not yet recruiting Phase 4 Interventional

Clinical Lid Eradication of Antifungal-Responsive FUNGUS Study

NCT07856680
View directory record Official record
Conditions
Anterior Blepharitis
Interventions
NATACYN®
Drug
Lead sponsor
Brent Kramer
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Jacksonville, Florida • Pittsburg, Kansas • Mint Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Phase 4 Interventional

Impact of XDEMVY® on Demodex Blepharitis in Soft Contact Lens Wearers

NCT06182358
View directory record Official record
Conditions
Demodex Blepharitis
Interventions
Lotilaner ophthalmic solution, 0.25%, Vehicle control
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Cave Creek, Arizona • Long Beach, California • Colorado Springs, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 21, 2026, 2:11 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex

NCT06054217
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Demodex Infestation of Eyelid, Blepharitis, Demodectic Blepharitis
Interventions
Vehicle of TP-03
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Northridge, California • Shelby, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis

NCT01102244
View directory record Official record
Conditions
Blepharitis
Interventions
Tobradex ST, Azasite
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 21, 2026, 2:11 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

NCT05145959
View directory record Official record
Conditions
Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses, Ocular Surface Disease, Meibomitis, Meibomian Gland Dysfunction, Dry Eye
Interventions
Maskin Probe
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 6, 2021 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD

NCT05454956
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Blepharitis, Demodex Infestation
Interventions
TP-03, TP-03 Vehicle
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Northridge, California • Kansas City, Missouri • Cary, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 21, 2026, 2:11 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Treatment of Anterior Blepharitis With Microblepharoexfoliation Procedure

NCT04290455
View directory record Official record
Conditions
Anterior Blepharitis
Interventions
Microblepharoexfoliative procedure with BlephEx™, Eyelid cleansing with eyelid wipes (Optase), Daily eyelid cleansing with eyelid wipes (Optase)
Device · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 21, 2026, 2:11 AM EDT
Completed No phase listed Observational

Evaluation and Treatment of Patients With Corneal and External Diseases

NCT00008541
View directory record Official record
Conditions
Blepharitis, Conjunctivitis, Corneal Disease, Dacryoadenitis, Dacryocystitis, Keratitis
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Phase 4 Interventional

Study of the Safety and Efficacy of Moxidectin Tablets for the Reduction of Demodex Eyelash Infestation

NCT06795165
View directory record Official record
Conditions
Blepharitis
Interventions
Moxidectin 2 MG Oral Tablet, Placebo
Drug
Lead sponsor
Eye Research Foundation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 21, 2026, 2:11 AM EDT
Recruiting Phase 2 Interventional

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

NCT07400965
View directory record Official record
Conditions
Demodex Blepharitis
Interventions
GLK-321 low dose BID, GLK-321 mid dose BID, GLK-321 high dose BID, GLK-321 high dose QD, Placebo BID
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Systane Versus Saline in Maintaining Tear Film Stability at Determined Time Points

NCT00345241
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Systane Ocular Drops (OTC), Placebo - Saline Drops
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 88 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2008 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Not applicable Interventional Results available

Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery

NCT01808560
View directory record Official record
Conditions
Blepharitis, Dry Eye Syndrome
Interventions
LipiFlow Pre-Treatment, LipiFlow Post-treatment
Device
Lead sponsor
TearScience, Inc.
Industry
Eligibility
55 Years to 85 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
7
States / cities
Hoffman Estates, Illinois • Lake Villa, Illinois • Winchester, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Oct 21, 2026, 2:11 AM EDT
Completed Phase 4 Interventional Results available

Comparative Study in the Efficacy of Topical Besifloxocin With Erythromycin for the Management of Acute Blepharitis

NCT01478256
View directory record Official record
Conditions
Blepharitis
Interventions
Erythromycin, Besifloxocin
Drug
Lead sponsor
John, George, M.D.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 21, 2026, 2:11 AM EDT